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Abstract: Breast cancer is one of the most common malignancies in women worldwide. In breast
cancer, the cell proliferation rate is known to influence the cancer malignancy. Recent studies have
shown that DNA replication initiation/licensing factors are involved in cancer cell proliferation as
well as cancer cell migration and invasion. Licensing factors have also been reported as important
prognostic markers in lung, prostrate, and bladder cancers. Here, we studied the role of MCM10,
a novel licensing factor, in breast cancer progression. From the public database, NCBI, we investigated
six independent breast cancer patient cohorts, totaling 1283 patients. We observed a significant
association between high MCM10 mRNA expression with tumor grading and patients’ survival
time. Most importantly, using breast cancer cohorts with available treatment information, we also
demonstrated that a high level of MCM10 is associated with a better response to conventional
treatment. Similarly, in in vitro studies, the expression level of MCM10 in breast cancer cell lines
is significantly higher compared to paired normal breast epithelium cells. Knockdown of MCM10
expression in the cancer cell line showed significantly decreased tumorigenic properties such as
cell proliferation, migration and anchorage independence. The MCF7 breast cancer cell line, after
MCM10 expression knockdown, showed significantly decreased tumorigenic properties such as cell
proliferation, migration, and anchorage independent growth. Mechanistically, MCM10 expression is
observed to be regulated by an Estrogen Receptor (ER) signaling pathway, where its expression is
suppressed by the inhibition of the ER or serum withdrawal. Our results suggest that MCM10 plays
an important role in breast cancer progression and is a potential prognostic/predictive biomarker
and therapeutic target for breast cancer patients.
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1. Introduction
Breast cancer is the second major cause of cancer related mortality in women, after lung cancer,
worldwide [1]. An increased cell proliferation rate is among the few key capabilities acquired by
cancerous cells. In normal cells, cell proliferation is tightly regulated by the binding of DNA licensing
factors such as CDC6, Cdt1 and Minichromosome Maintenance proteins (MCM) proteins (MCM2-7)
onto DNA replication initiation sites. We, along with others, have previously observed the high
expression of CDC6, CDT1 and MCM2-7 proteins in breast cancer progression [2–4]. Alterations in
the expression profiles of the licensing proteins have been linked to various aspects of cancer [5,6]
such as cancer cell proliferation [7,8] and cancer invasion [9]. High expression of CDC6, CDT1 and
MCM family proteins may initiate replication at multiple regions on the DNA, thereby facilitating
cancer cell proliferation. Depletion of some of these licensing factors, in vitro, is known to reduce
cell proliferation as well as induce programmed cell death [10]. Therefore, DNA licensing factors
have been reported as important prognostic markers in cancers such as lung, prostrate, and bladder
cancers [2]. Reduction of MCM proteins in cancer cells is known to induce sensitivity to drugs such as
aphidicolin, camptothecin, hydroxyurea, etc., and thereby promote an anti-proliferative effect [11,12].
Hence, DNA licensing factors may be a potential target for future chemotherapy or for combinatorial
therapy against cancer.
During replication, MCM10, a subtype of the MCM family, is essential for replication origin
firing [13]. MCM10 along with other proliferative markers initiate DNA replication in late G1 or
early S phase of cell cycle, thereby mediating cell proliferation. MCM10 protein is also known to
recruit DNA polymerase-α as well as regulate its catalytic subunit, preventing the elongation of the
damaged DNA [14,15]. Depletion of MCM10 has been observed to regulate the turnover of DNA
polymerase-α [15]. MCM10 is also known to interact with other replication protein complexes such as
the MCM2-7 complex, Replication protein A and Proliferating cell nuclear antigen (PCNA), thereby
maintaining a steady state during DNA replication [2]. Consequently, dysregulation of MCM10 protein
may lead to genomic instability and replication stress, which can, in turn, induce tumorigenesis [16].
MCM10 was shown to be upregulated in a neuroblastoma cell line [17], overexpressed in pancreatic,
cervical, esophageal and urothelial cancers [18–21] and mutated in early gastric cancer specimens [22].
In cervical and urothelial cancers, high expression of MCM10 has been associated with a higher grade
cancer or malignant cancer [18,19]. MCM10 was determined as one of the top-ranked genes that is
enriched in cancer-associated pathways [23]. High MCM10 can initiate multiple DNA replication
origins along with origins that serve as a backup origin on DNA [24]. This could shorten replication
time and promote DNA mismatch, thereby promoting genomic instability. For instance, altered
initiation of replication especially during DNA damage response could lead to carcinogenic event [25].
Alterations in replication timing and progression (replication stress) may drive the malignancy in
cancer cells thereby lower survival of cancer patients. Although the exact mechanism on regulation of
MCM10 is still unknown, high expression of MCM10 can serve as an indicator of cancer progression.
In the present study, we focused on understanding the importance of MCM10 and its regulation
during breast cancer progression by using publicly available breast cancer patient cohorts, in vitro cell
line experiments and in vivo mouse models.
2. Results
2.1. Association between MCM10 Expression and Tumor Grade
Six independent breast cancer patient cohorts, which we have used for studying MCM2-7 genes
previously [4] using the Affymetrix platform, were included in the present study. Four out of the six
independent breast cancer patient datasets have available information on tumor grading; therefore,
we compared the expression level of MCM10 mRNA between tumors with different grades in these
four datasets. MCM10 mRNA expression was consistently and significantly higher in tumors with
a higher grade, in GSE1456 (n = 147, p < 0.001; Figure 1A), GSE3494 (n = 234, p < 0.001; Figure 1B),
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GSE7390 (n = 198, p < 0.001; Figure 1C) and GSE11121 (n = 200, p < 0.001; Figure 1D). In addition,
three out of the six independent breast cancer patient datasets had available information on Estrogen
Receptor (ER) status. We also compared the expression level of MCM10 mRNA between tumors
with different ER statuses. MCM10 mRNA expression was consistently and significantly higher in
ER negative breast cancer compared to ER positive breast cancer in GSE2034 (n = 286, p < 0.001;
Figure 1E), GSE3494 (n = 232, p < 0.001; Figure 1F) and GSE7390 (n = 198, p < 0.001; Figure 1G). Our
results suggest that MCM10 expression is regulated by ER signalling. Since the availability of data
varies among the datasets included in the current study, we also analysed whether MCM10 expression
is an independent prognostic marker in different conditions (Table 1). We have shown, by using
Cox-regression analysis, that MCM10 expression predicted disease-specific events independent of
histological grade (Supplementary Figure S1; MCM10: Hazard Ratio = 1.908, 95% CI = 1.362–2.671,
p < 0.001; Grade: p = 0.048) in the combined dataset and independent of subtype (Supplementary
Figure S2; MCM10: Hazard Ratio = 4.658, 95% CI = 2.132–10.179, p < 0.001).
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Figure 1. The association between MCM10 expressions, tumor grade and estrogen receptor status. 
Box plots showing the mean, 95% confidence interval and range of MCM10 mRNA expression in 
breast cancer datasets in tumors with different histologic grade in (A) GSE1456 (n = 147); (B) GSE3494 
(n = 234); (C) GSE 7390 (n = 196) and (D) GSE11121 (n = 200); the association between MCM10 
expressions and estrogen receptor status. Box plots showing the mean, 95% confidence interval and 
range of MCM10 mRNA expression in breast cancer datasets in tumors with different estrogen 
receptor status in (E) GSE2034 (n = 286); (F) GSE3494 (n = 232) and (G) GSE7390 (n = 198). 
Table 1. Clinicopathological details of six different data sets used in the paper. 
Dataset 
Sample 
Size 
Year of the 
Associated 
Publication 
Available Clinical 
Parameters 
Patient Characteristics (Percent) 
GSE1456 
[26] 159 2005 
Grade 
Grade 1 (18) 
Grade 2 (37) 
Grade 3 (38) 
Missing (7) 
Subtype 
Luminal A (25) 
Luminal B (15) 
Basal (16) 
HER2 (9) 
Normal-like (23) 
Missing (13) 
GSE2034 
[27] 
286 2005 
ER status 
ER negative (27) 
ER positive (73) 
Brain relapse status 
With brain relapse (97) 
Without brain relapse (3)  
GSE3494 
[28] 
251 2005 
Grade 
Grade 1 (27) 
Grade 2 (51) 
Grade 3 (22) 
Missing (1) 
ER status 
ER negative (14) 
ER positive (85) 
Missing (2) 
PR status 
PR negative (24) 
PR positive (76) 
Age at diagnosis Mean = 62 year (SD = 14) 
Tumor size Mean = 22 mm (SD = 13) 
Lymph node involvement 
Negative (63) 
Positive (34) 
Missing (4) 
GSE7390 
[29] 
198 2007 
ER status 
ER Negative (32) 
ER Positive (68) 
Grade 
Grade 1 (15) 
Grade 2 (42) 
Grade 3 (42) 
Missing (1) 
Age Mean = 46 (SD = 7) 
Tumor size Mean = 22 mm (SD = 8) 
GSE11121 200 2008 Grade Grade 1 (15) 
Figure 1. The association between MCM10 expressions, tumor grade and estrogen receptor status.
Box plots showing the mean, 95% confidence interval and range of MCM10 mRNA expression in
breast cancer datasets in tumors with different histologic grade in (A) GSE1456 (n = 147); (B) GSE3494
(n = 234); (C) GSE 7390 (n = 196) and (D) GSE11121 (n = 200); the association between MCM10
expressions and estrogen receptor status. Box plots showing the mean, 95% confidence interval and
range of 10 mRNA expression in breast cancer datasets in tumors with different estrogen receptor
status in (E) GSE2034 (n = 286); (F) GSE3494 (n = 232) and (G) GSE7390 (n = 198).
Table 1. Clinicopathological details of six different data sets used in the paper.
Dataset Sample Size Year of the AssociatedPublication
Available Clinical
Parameters
Patient Characteristics
(Percent)
GSE1456 [26] 159 2005
Grade
Grade 1 (18)
Grade 2 (37)
Grade 3 (38)
Missing (7)
Subtype
Luminal A (25)
Luminal B (15)
Basal (16)
HER2 (9)
Normal-like (23)
Missing (13)
GSE2034
[27] 286 2005
ER status ER negative (27)ER positive ( 3)
Brain relapse status With brain relapse (97)Without brain relapse (3)
GSE3494
[28] 251 2005
Grade
Grade 1 (27)
Grade 2 (51)
Grade 3 (22)
Missing (1)
ER status
ER negative (14)
ER positive (85)
Missing (2)
PR status PR negative (24)PR positive (76)
Age at diagnosis Mean = 62 year (SD = 14)
Tumor size Mean = 22 mm (SD = 13)
Lymph node
involvement
Negative (63)
Positive (34)
Missing (4)
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Table 1. Cont.
Dataset Sample Size Year of the AssociatedPublication
Available Clinical
Parameters
Patient Characteristics
(Percent)
GSE7390
[29] 198 2007
ER status ER Negative (32)ER Positive (68)
Grade
Grade 1 (15)
Grade 2 (42)
Grade 3 (42)
Missing (1)
Age Mean = 46 (SD = 7)
Tumor size Mean = 22 mm (SD = 8)
GSE11121
[30] 200 2008
Grade
Grade 1 (15)
Grade 2 (68)
Grade 3 (18)
Tumor size Mean = 21 (SD = 10)
GSE12276
[31] 204 2009 Site of relapse
Local (9)
Other (83)
Brain (4)
Brain and other (4)
Note: HER2, Human Epidermal Growth Factor Receptor 2; ER, Estrogen Receptor; PR, Progesterone Receptor.
2.2. Association between MCM10 Expression and Patient Survival
A high expression level of MCM10 in tumor specimens was associated with a shorter survival
time in all six breast cancer patient datasets tested (n = 1283). In GSE1456 (n = 159), patients with a high
MCM10 expression level had a mean survival time of 6.2 years (95% CI = 5.5–6.8 years) versus 7.9 years
(95% CI = 7.6–8.3 years) for those with a low MCM10 expression level (p < 0.001; Figure 2A). In GSE2034
(n = 286), patients with a high MCM10 expression level had a mean survival time of 9.2 years (95%
CI = 8.3–10.2 years), while those patients with a low MCM10 expression level had a mean survival time
of 10.4 years (95% CI = 9.5–11.3 years, p = 0.057; Figure 2B). In GSE3494 (n = 236), patients with a high
MCM10 expression level had a mean survival time of 9.6 years (95% CI = 8.7–10.5 years), while those
with a low MCM10 expression level had a mean survival time of 11.4 years (95% CI = 10.9–12.0 years,
p = 0.001; Figure 2C). In GSE7390 (n = 198), patients with a high MCM10 expression level had a mean
survival time of 17.0 years (95% CI = 14.8–19.3 years), while those with a low MCM10 expression
level had a mean survival time of 19.0 years (95% CI = 17.5–20.5 years, p = 0.013; Figure 2D). Similar
results were obtained from GSE11121, where patients with tumors expressing low MCM10 levels had a
significantly longer survival compared to those with tumors expressing high MCM10 levels (p = 0.006;
Figure 2E). For those patients with metastatic breast cancer, from GSE12276 (n = 204), the median
survival for patients with a high MCM10 expression level was only 1.3 years and 2.1 years for those
with a low MCM10 expression level (p < 0.001; Figure 2F). Summary of the survival analysis in breast
cancer patient datasets is attached in (Table 2). Since the observations were consistent among all six
independent breast cancer patient datasets, our results strongly suggest that MCM10 alone could be a
prognostic marker for breast cancer patients.
Table 2. Summary of the survival analysis in breast cancer patient datasets.
Dataset No. of Patients p-Value
GSE1456 159 <0.001
GSE2034 286 0.057
GSE3494 236 0.001
GSE7390 198 0.013
GSE11121 200 0.006
GSE12276 204 <0.001
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Figure 2. The association between MCM10 expressions and patient survival. Kaplan-Meier plots
showing the proportion of patient survival for those with low or high MCM10 expression levels in
breast cancer datasets (A) GSE1456 (n = 159); (B) GSE2034 (n = 286); (C) GSE3494 (n = 236); (D) GSE7390
(n = 198); (E) GSE11121 (n = 200); and (F) GSE12276 (n = 204).
2.3. MCM10 Protein Level Was Increased in Human Breast Cancer Specimens
To validate our observation from the publicly available breast cancer patient datasets, we analyzed
the expression of MCM10 by qPCR and immunohistochemistry from 16 pairs of normal and tumor
samples obtained from breast cancer patients having a biopsy in the First Affiliated Hospital of Fujian
Medical University. MCM10 mRNA expression was found to be significantly higher (p = 0.006) in
tumor samples compared to the respective normal tissue. (Figure 3A) The results didn’t correlate to
any of clinicopathological details of patients (Supplementary Table S1). Similarly, protein expression
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of MCM10 was significantly higher in tumor specimens compared to its normal breast epithelium
counterparts (Figure 3B,C), confirming our observation using microarray data in six independent
breast cancer patient cohorts.
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Figure 3. MCM10 expression in patient tumor biopsy. (A) MCM10 expression quantified by qPCR in
paired normal and tumor biopsy samples (n = 16, *** p = 0.006); (B,C) immunohistochemistry staining
of patients’ biopsy, High MCM10 DAB staining is observed in patients’ biopsies; (C) compared to
normal breast tissue (B). Magnified images showing nuclear staining of MCM10, in red arrows.
2.4. MCM10 Expression Was Increased in Breast Cancer Cell Lines
We further studied the expression of MCM10 in breast cancer cell lines. MCF 10A is a normal
breast cell line that we used to compare with two different breast cancer cell lines, MCF 7 (ER-positive;
less aggressive) and MDA 231 (triple negative; more aggressive). We found a significantly increased
expression of MCM10 in both MCF 7 and MDA 231 cells compared to MCF 10A cells. Furthermore,
MCM10 expression was also significantly higher in MDA 231 cells when compared to MCF-7 cells
using both the protein and mRNA levels for comparison (Figure 4A,B).
2.5. MCM10 Expression Was Regulated by Growth Signalling
To investigate whether MCM10 expression is regulated by a proliferation signal, MDA 231 cells
were incubated in media with or without serum for 24 h, and the expression of MCM10 was tested. We
observed a significant increase in MCM10 expression level both in qPCR and Western blot for MDA
231 cells grown in media containing serum compared to the cells that grew in media without serum.
However, the increase in MCM10 expression from the addition of serum was not observed when
the cells were treated with aphidicolin, which blocked cell cycle progression, indicating that MCM10
expression is associated with cell proliferation in breast cancer cells (Figure 4C,D). ER signaling is an
important growth signal for breast cancer. While there was a differential expression of MCM10 in ER
positive MCF-7 cells compared to ER negative MDA-MB-231 cells, we further investigated whether
MCM10 expression is regulated by ER signaling. We found that, when ER positive MCF-7 cells were
treated with tamoxifen, the mRNA and protein expression of MCM10 decreased starting at six hours
and lasted 24 h post-treatment (Figure 4E,F).
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Tamoxifen treatment to MCF 7 cells reduced MCM10 expression in a time d pende t manner observed
by qPCR and Western blots. (n = 3, * p < 0.05).
2.6. Knockdown of MCM10 Decreased Cell Proliferation, Cell Migration and Anchorage Independent Growth
To investigate how MC 10 may contribute to breast cancer progression, we knocked down
MCM10 expression in MCF 7 cells and then tested the cellular properties, including cell proliferation
and migration. As shown in Figure 5A,B, knockdown of MCM10 resulted in decreased expression
of MCM10 at both the mRNA and protein levels. Knockdown of MCM10 did not increase apoptosis
in MCF 7 cells compared to the control cells, suggesting that MCM10 is not essential for cell survival
(Figure 5C). On the other hand, MCM10 knockdown MCF 7 cells had a significantly lower proliferation
rate compared to the control MCF 7 cells (Figure 5D,E). Indeed, we also observed a significant reduction
in cyclin D1 expression in the MCM10 knockdown MCF 7 cells, suggesting cell proliferation was
impaired when MCM10 expression was knocked down (Figure 5F). Similarly, MCM10 knockdown
MCF-7 cells also had a significantly lower migration and soft agar colony formation potential,
suggesting that reducing the expression of MCM10 may reduce the aggressiveness of breast cancer cells
(Figure 5G–I). However, further increasing the level of MCM10 by ectopic expression did not further
increase cell proliferation and migration in MCF-7 cells (Supplementary Figure S3). Overexpression of
MCM10 in MCF 7 cells did not reverse our earlier observation in MCM10 KD cells (Supplementary
Figure S3B–E). Overexpression monitored by FLAG tag expression showed that the level of MCM10
proteins was indeed maintained in steady state by unknown regulatory mecha ism in MCF 7 cells.
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Figure 5. Cancer hallmarks of stable MCM10 knockdown (KD) in MCF 7 cells. (A,B) relative expression
of MCM10 in stable MCM10-KD CF 7 cell lines assessed by qPCR and Western blots (n = 3,
*** p < 0.001); (C) apo tosis analysis by Annexin V/Propidium Iodide flow cytometry showed no
difference between stable 10-control F7 cell lines and stable CM10-KD MCF 7 cell lines
(n = 3, * p < 0.05); (D) following MCM10 KD, the MCM10-KD MCF7 cells showed a decrease in
cell proliferation monitored for seven days using phase contrast i ages in Incucyte ZOOM analysis
software (n = 6); (E) MTT assay using stable cells showed a similar observation indicating decreased
proliferation in MCM10-KD MCF 7 cells (n = 3, * p < 0.05); (F) analysis cell cycle markers by western
blot and QPCR showed a decrease in cycling D1 expression indicating impaired cell proliferation in in
MCM10-KD MCF 7 cells (n = 3, * p < 0.05); (G) wound healing migration assay performed by using
Incucyte ZOOM showed a decrease in cell migration in MCM10-KD MCF 7 cell lines. Wound heal
quantified by relative Gap size using Incucyte ZOOM software (n = 6, * p < 0.05); (H) Transwell cell
migration assay was used to confirm our observation and showed a similar decrease in the number of
migrating cells in MCM10-KD MCF 7 cells (n = 3, ** p < 0.01); (I) colony formation assay performed
using soft agar showed a decrease in the number of colonies in MCM10-KD MCF 7 cells compared to
the control cells. (n = 3, * p < 0.05).
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2.7. MCM10 Expression Correlated with Tumor Growth In Vivo
To further understand the effect of MCM10 knockdown on tumor growth in vivo, we grafted
MCF 7 knockdown cells into the mammary fat pad of nude mice. Tumor volume was measured
weekly, and all mice were sacrificed at the end of experiment when tumors were dissected and
weighed. The inhibitory effect of MCM10 knockdown on the growth of breast tumors was significant
in xenograft model mice. Tumor growth was slower and a significant difference was observed on
the 12th week after cell grafting (Figure 6A,B). We isolated the tumor on the 14th week and analyzed
expression of MCM10 using qPCR (Figure 6C). The tumors formed by MCM10 knockdown cells
showed a significant decrease in MCM10 expression compared to the control cells, suggesting that
reduction of MCM10 also reduced tumor growth in vivo in mice models.
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2.8. Association between MCM10 Expression and Treatment Response
We went on to investigate whether expression of MCM10 was associated with response to
treatment. Three independent breast cancer patient datasets with treatment details (chemotherapy
with or without trastuzumab depending on the HER2 status) and response to treatment were included
in the analysis. In GSE22226 (n = 124), patients who achieved pathological complete response (pCR)
after neoadjuvant treatment had a significantly higher expression of MCM10 compared to those
patients who did not achieve pCR after treatment (p = 0.037; Figure 7A). In GSE22358 (n = 122), patients
who achieved near complete response or complete response had a higher level expression of MCM10
compared to those patients who had only partial response or no response to the neoadjuvant treatment
(p = 0.002; Figure 7B). Similarly, in GSE42822 (n = 91), patients who achieved pCR had a significantly
higher expression of MCM10 compared to those who did not achieve pCR (p = 0.014; Figure 7C).
These consistent results obtained in three independent breast cancer datasets suggest that tumors
with higher MCM10 expression may be more prompt to respond to neoadjuvant treatment. Further
to this observation, we found that MCM10 expression was associated with survival, especially in
those patients who did not achieve a pCR during neoadjuvant treatment. Similar to the other six
independent breast cancer datasets, in GSE22226, even with standard neoadjuvant treatment, patients
with a high level expression of MCM10 had a significantly shorter survival time compared to those
with a low level expression of MCM10 (p = 0.013; Figure 7D). Importantly, in patients who did not
achieve pCR, a high level expression of MCM10 was associated with a shorter survival time (p = 0.001;
Figure 7E), while, in patients who achieved pCR, there was no significant association between MCM10
expression and survival (p = 0.871; Figure 7F). These results suggest that MCM10 could be a potential
prognostic marker to stratify which patients should require more intensive adjuvant treatment when
pCR could not be achieved via neoadjuvant treatment.
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3. Discussion
DNA replication is a highly regulated process in the cell. The MCM protein complex plays a
vital role as DNA helicases during replication. Excess MCM proteins are known to maintain genomic
integrity by acting as dormant origins that serve as a backup during replication [24]. MCM10 initiates
DNA replication by activating MCM replication complex, which implies that its dysregulation may
contribute to uncontrollable proliferation, thereby, leading to cancer development [18–21]. However,
to our best knowledge, no report has extensively investigated the significance of MCM10 in breast
cancer. In the present study, we have demonstrated that (i) MCM10 was highly expressed in human
breast cancer specimens compared to normal breast epithelium, in vitro and (ii) a high MCM10
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expression level was associated with a significantly shorter time of breast cancer patient survival.
We demonstrated that (iii) MCM10 expression is required for cell proliferation and migration in
ER-positive breast cancer cells, in which knockdown of MCM10 resulted in reduction in these cellular
properties. These results indicate a positive correlation between DNA replication and breast cancer cell
proliferation. These results also suggest a use of MCM10 as a prognostic marker as well as a potential
therapeutic target for breast cancer.
In total, six independent breast cancer patient cohorts with 1283 individual patients were included
in the present study for the survival analysis; the robust results from these six independent cohorts
suggest that the association between MCM10 expression and patient survival was consistent. Since
MCM10 expression is associated with cell cycle progression and cell proliferation [32–34], it is not
surprising that tumors with high MCM10 expression levels responded to chemotherapy that targets
fast growing cells. Consistently, observed in three independent datasets, breast cancer patients who
achieved pCR by neoadjuvant chemotherapy had a significantly higher MCM10 expression level.
Another important observation in this study is that patients who had low MCM10 expression level
and achieved pCR by neoadjuvant therapy could survive significantly longer than those patients
who achieved pCR but had a high MCM10 expression level, suggesting that patients with a high
expression level of MCM10 may have a greater chance of recurrence even achieving pCR during
neoadjuvant therapy.
Loss of MCM proteins has previously been reported to reduce proliferation of cancer cells [11,35].
Serum deprivation itself induced a significant reduction in MCM10 expression as well as cell
proliferation. Knockdown of MCM10 in ER positive breast cancer cells also reduced cell proliferation
rate and cancer migration. Reduction of cancer cell properties after MCM10 knockdown in ER positive
breast cancer cells was in parallel to three independent ER-positive breast cancer patient cohorts
with less expression of MCM10 and longer survival time. In addition, these MCM10 knockdown
cells had a slower growth rate compared to control cells in vivo, suggesting that MCM10 plays an
important role in cancer-related properties in breast cancer cells. Overexpression of MCM10 in MCF 7
cells (Supplementary Figure S1), monitored by stable expression of FLAG tag, did not affect the
proliferation rate or any of the key hallmarks of cancers. This observation indicates presence of a
regulatory mechanism that maintains a steady state of MCM10 within the cell. Hence, studies on
post-translational regulation of MCM10 are required to analyze the activation and initiation mechanism
of MCM10 during cancer. However, the potential utility of reducing MCM10 in cancer therapy is not
clear; nonetheless, it can decrease initiation of DNA replication. MCM10 downregulation can block
dormant DNA replication origins that serve as backup during replication [24]. Targeting MCM10
also plays an important role when using anti-cancer agents such as platinum based drugs, 5-fluoro
uracil, etc., which bind to DNA forming DNA lesions. Thus, targeting MCM10 can increase the
therapeutic potential of conventional drugs. Reduction of MCM proteins in cancer cells is also known
to induce sensitivity to drugs that block replication fork progression such as aphidicolin, camptothecin,
hydroxyurea, etc., and thereby promoting anti-proliferative effect [11,12].
Estrogen receptors play an important role in breast cancer development and progression. MCM2,
MCM6 and MCM7 have been shown to be regulated by ER signaling [26,36,37]. ER signaling was
also associated with an increase in MCM10 expression in vivo [37]. In female mice, treatment of
estradiol induced increased proliferation of natural killer cells by upregulating MCM7 and MCM10
expressions [37]. Using the ER positive MCF 7 cells, we found that the blockade of the ER signaling by
tamoxifen resulted in a significant reduction in MCM10 expression. These results suggest that MCM10
is a downstream factor of ER signaling in breast cancer cells. However, stimulation using estradiol
showed perplexing results. In parallel to this observation, in ER-negative breast cancer cohorts and
also in ER-negative MDA MB 231 cells, MCM10 expression was significantly higher compared to
ER-positive specimens/cells. The previous evidence also indicates differential regulation of MCM10.
Studies indicate that ER-negative breast cancer cells seems to have extensive deregulations in their
estrogen receptor pathway since restored ER expression in ER-negative breast cancer cells did not
Cancers 2018, 10, 282 13 of 19
restore the ability of estrogen to stimulate proliferation [27]. Nonetheless, the regulation of MCM10 may
be vital for both ER-positive and ER-negative breast cancer cells, which needs further investigation.
4. Materials and Methods
Ethics approval and consent to participate: all animal handling was approved by the University of
Macau Animal Ethics Committee (UMARE-012-2016). Study participants signed an informed consent
to allow research assays to be carried out on their tumor tissue. A Medical Ethics Committee at the
First Affiliated Hospital of Fujian Medical University approved the study ([2015]108).
4.1. Extraction of Clinical and Microarray Gene Expression Data from Breast Cancer Patient Datasets
Six independent breast cancer patient datasets, GSE1456 [28], GSE2034 [29], GSE3494 [30],
GSE7390 [31], GSE11121 [38] and GSE12276 [39], each comprising 150 or more patients, with available
data on patient survival, clinicopathological parameters and MCM10 gene expression in the Gene
Expression Omnibus (GEO) Database were included in this study, while three independent breast
cancer patient datasets, each comprised of 80 or more patients, GSE22226 [40], GSE22358 [41] and
GSE42822 [42], with available information on response to treatment, hormonal and HER2 receptor
status were also included. Microarray gene expression data were retrieved from the data matrixes
deposited to the GEO database by the original authors. R scripting was used to extract the expression
values of genes (probesets) of interest and the clinical data from the data matrixes were downloaded
from GEO.
4.2. Correlations of Gene Expression Levels and Clinical Data
All statistical analyses were performed using SPSS19.0 (IBM Corp., Armonk, NY, USA).
The associations between expression level of MCM10 and tumor grade, between expression level of
MCM10 and ER-status, between expression level of MCM10 and treatment response, and between
expression level of MCM10 and triple negative status were tested by ANOVA or Welch’s t-test where
applicable depending on the p-value of homogeneity test. Expression levels were divided into high
and low levels using median expression level as the cut-off point for Kaplan–Meier survival analysis.
Results were compared by a Wilcoxon–Gehen test.
4.3. Cell Culture and Reagents
All cell lines were obtained commercially from ATCC (American Type Culture Collection,
Manassas, VA, USA). MCF10A were maintained in Dulbecco’s Modified Eagle Medium: Nutrient
Mixture F-12 (DMEM/F12) (Gibco, Carlsbad, CA, USA) supplemented with 5% horse serum, 20 ng/mL
EGF (Peprotech, Rocky Hill, NJ, USA), 0.5 µg/mL hydrocortisone (Sigma-Aldrich, St. Louis, MO,
USA), 100 ng/mL cholera toxin (Sigma-Aldrich) and 10 µg/mL insulin (Sigma-Aldrich). MCF7 were
maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) with 10% FBS, 1% sodium
pyruvate (Gibco), 1% L-glutamine and 10 µg/mL insulin (Sigma-Aldrich). MDA-MB-231 were
maintained in DMEM (Gibco) supplemented with 10% FBS, 1% sodium pyruvate (Gibco), and
1% L-glutamine. HEK-293T cells (provided by Dr Joong Sup SHIM, University of Macau, Macau
SAR, China) and Phoenix-AMPHO (purchased from ATCC) for lentiviral and retroviral packaging,
respectively, were maintained in DMEM supplemented with 10% FCS. The medium for all cell lines
was supplemented with 1% Pen/ Strep (Gibco) except when otherwise noted. All cells were cultured
in an incubator with a humidified atmosphere maintained at 5% CO2 and 95% air at 37 ◦C. For the
soft agar, migration and invasion assays, phenol red-free DMEM was used. All cells were free of
mycoplasma contamination.
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4.4. Transfection
MCM10 expression was silenced in MCF7 cells using specific shRNA (TRCN0000245427:
5′CCGGAGATGCAGGAGCGCTACTTTGCTCGAGCAAAGTAGCGCTCCTGCATCTTTTTTG3′)
(Sigma) against MCM10. Lentiviruses were packaged using expression plasmid, constructed using
expression vectors: pCI-VSVG (#1733) and pCMV-dR8.2 dvpr (#8455) (Addgene, Cambridge, MA,
USA) along with the shRNA using Lipofectamine 2000 according to manufacturer’s instructions.
The lentivruses were produced and delivered to the MCF-7 cells to create a stable MCM10 knockdown
cell line.
To upregulate MCM10 expression in MCF7 cells, retroviruses were first prepared using expression
vectors containing pBabe-puro-MCM10-3Xflag or expression vectors alone (both vectors were obtained
from Lin Yao from Fujian Normal University, Fujian, China) and transfected into Phoenix-AMPHO
cells using Lipofectamine 3000, according to the manufacturer’s instructions. The retroviruses were
then introduced to MCF7 cells to create a stable MCM10 overexpression cell line. All constructions
used were sequenced and confirmed to be correct.
4.5. Quantitative qPCR
MCF10A, MCF7 and MDA-MB-231 cells were seeded at a density of 2 × 105 cells/well on 6-well
plates. Cells were then harvested by cell scraping in RLT lysis buffer and total RNA was isolated using
RNeasy Mini Kit and QiaShredder (Qiagen, Valencia, CA, USA) according to the manufacturer’s
instructions. RNA quantity and quality were measured using Nanodrop™ spectrophotometer
(NanoDrop Technologies, Waltham, MA, USA). First strand cDNA synthesis was performed from 1 µg
total RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA,
USA) on a BioRad C1000 Touch™ Thermal Cycler (BioRad, Hercules, CA, USA). qRT-PCR analysis was
performed using the M×3005P qPCR System (Agilent, Santa Clara, CA, USA) and TaqMan® Universal
PCR Master Mix (Applied Biosystems) and Taqman probes specific for mcm10 and house-keeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The Taqman probes (mcm10, Hs00960349_m1
and GAPDH, Hs02758991_g1) were purchased from ThermoFisher Scientific (Waltham, MA, USA). For
Cyclin D1 and CDK4 analysis, we used in-house designed primers. Fold change in gene expression
was normalized to GAPDH and compared to the untreated value using the 2−∆∆CT formula.
4.6. Western Blotting
Cells were seeded in T25 flask, harvested using cell scrapers and suspended in RIPA buffer
(150 mM NaCl; 5mM EDTA, 50 mM Tris, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS)
supplemented with protease inhibitor (Roche, St. Louis, MO, USA) and phosphatase inhibitor
(Roche). Protein samples were incubated for 30 min at 4 ◦C with intermittent agitation after
which they were centrifuged for purification and quantified using BCA protein assay (ThermoFisher
Scientific). The proteins were separated by 4–12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
and electrophoretically transferred to a nitrocellulose membrane (Millipore, Hercules, CA, USA)
on a Mini Trans-Blot Electrophoretic Transfer Cell (BioRad, Hercules, CA, USA). The membrane
containing the transferred protein was blocked with 3% non-fat milk at room temperature for an
hour. Target proteins were detected by incubating the membrane at 4 ◦C overnight with primary
anti-MCM10 antibody (Bethyl, Montgomery, TX, USA) (1:1000), anti-Cyclin D1 antibody (#2922
Cell Signaling Technology, Beverly, MA, USA) (1:1000), anti-CDK4 antibody (#12790 Cell Signaling
technology) (1:1000), anti-FLAG antibody (#F1804-5MG Sigma Aldrich, Taufkirchen, Germany) (1:5000)
and primary anti-β-actin antibody (Santa Cruz Biotechnologies, Dallas, TX, USA) (1:5000) (1:5000).
The appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000) (Santa Cruz
Biotechnologies, Dallas, TX, USA) were applied to the membrane and incubated at 1 h at room
temperature. Positive bands were detected using Immobilon Western Chemilum HRP substrate (Merck
Millipore, Billerica, MA, USA). Blots were visualized on ChemiDoc Touch Imaging System (BioRad).
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Quantitation of immunoreactive signals was carried out by densitometry using ImageJ 1.46r software
(NIH, Bethesda, MA, USA). The value of each band was normalized to β-actin.
4.7. Cell Proliferation by Incucyte Zoom
To monitor the proliferation rate, cells were seeded at 2.25 × 104 cells per well in full growth
media on 12-well, clear bottomed, tissue culture plates (ThermoFisher Scientific). The plate was then
inserted into the IncuCyte (Essen Bioscience, Ann Arbor, MI, USA) for real-time imaging, with sixteen
fields imaged per well under 10×magnification every 2 h for a total of 4 days. Data were analyzed
using the IncuCyte Zoom software (version 2014a Essen Bioscience, Ann Arbor, MI, USA), which
quantified cell surface area coverage as confluence values. All IncuCyte experiments were performed
in triplicate.
4.8. MTT Assay
Cells were treated at 5 × 103 on 96-well, clear bottomed, tissue culture plates (ThermoFisher
Scientific) in 200 µL complete growth medium. The MTT assay was applied to study the cell viability
after 96 h. Cells were rinsed once with PBS (Gibco), and incubated with serum-free medium containing
20 µL of 0.4 mg/mL MTT at 37 ◦C and 5% CO2 for 4 h. The MTT solution was then removed, and
150 µL of dimethylsulfoxide (Sigma) was added into each well, and the plates were shaken for 10 min.
The optical densities of the supernatant were read at 555 nm using a microplate spectrophotometer
(Spectra Max 340, Molecular Devices, San Jose, CA, USA).
4.9. Wound Healing Assay
Cells were assessed in wound healing scratch assays using the IncuCyte (Essen Bioscience). Cell
migration assays were achieved by growing MCF7 and MDA-MB-231 cells to confluence in 96-well
plates (Essen BioScience; cat. no. 4379). Wounds were made using the 96-pin wound-making tool
(WoundMaker; Essen Bioscience) to simultaneously create a precise and reproducible wound in each
well, 1 h after the plate was washed twice with PBS, and incubated with DMEM containing 1% FBS, 1%
penicillin-streptomycin (Gibco), 4 mM L-glutamine (Gibco), sodium pyruvate (1 mM) and 0.01 mg/mL
bovine insulin (Sigma). Cell migration was monitored in real time by IncuCyte, and wound width was
measured by the IncuCyte software Zoom (version 2014a, Essen Bioscience, Ann Arbor, MI, USA).
4.10. Transwell Migration Assay
The migration ability of cells was detected using CytoSelect™ 24-Well Cell Migration (Cell Biolabs,
San Diego, CA, USA) according to manufacturer’s instructions. Briefly, cells were starved overnight
prior to the running of the assay. In addition, 1 × 106 cells/well were seeded in the upper chamber
with 300 µL of serum-free medium. The bottom chamber received 500 µL of full medium. After 24 h,
the media from inside of the insert was aspirated and non-migratory cells were cleaned using cotton
swabs. The inserts were then transferred to a clean well containing 400 µL of cell stain solution and
incubated for 10 min at room temperature. The stained inserts were then washed a few times in a
beaker of water and allowed to air dry and the migratory cells were counted under a light microscope
(Carl Zeiss Axio Observer, Oberkochen, Germany).
4.11. Soft Agar Colony Formation Assay
Cells were collected and mixed at a density of 2.5 × 105 cells mL−1 with 0.6% low melting point
agarose (Lonza, Basel, Switzerland) in complete DMEM phenol red-free medium containing growth
medium for a final concentration of 0.3% agarose. The cell mixture was plated on top of a solidified
layer of 0.6% agarose in growth medium. Cells were fed every 3–4 days with growth medium. Colonies
greater than 50 µm 22 days post-plating, were counted and photographed at 10× magnification under
a microscope (Leica M165FC stereomicroscope, Buffalo Grove, IL, USA) and analyzed using ImageJ
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1.46r software (NIH, Bethesda, MA, USA). At least two independent experiments were performed
in triplicate.
4.12. Drug Assay
Cells were seeded at a density of 2 × 105 cells/well in 6-well plates and allowed to attach
overnight. MCF-7 cells were then treated with tamoxifen (20 µM, Sigma) and incubated at 37 ◦C in a
humidified atmosphere with 5% CO2. Tamoxifen treatment cells were then collected at 0 h, 6 h, 12 h
and 24 h for qPCR and Western blot analysis. To block cell proliferation, MDA 231 cells were treated
with 25 µM Aphidicolin.
4.13. Assessment of Apoptosis
Apoptosis was investigated with the Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit
(ThermoFisher Scientific) as per the manufacturer’s instructions, on a BD Accuri C6 Flow Cytometer
(BD Biosciences, Franklin Lakes, NJ, USA).
4.14. Immunohistology
Patient samples were obtained from breast cancer patients at the First Affiliated Hospital of
Fujian Medical University with Medical Ethics Committee of the First Affiliated Hospital of Fujian
Medical University approval (approval number: [2015]108, Date: January 2015). The samples were
immersion fixed followed by dehydration in ethanol and embedded in paraffin wax. The tissues were
cut, sectioned and mounted on SuperFrost Plus Slides (ThermoFisher Scientific). The sections were
then de-paraffinized in xylene overnight and rehydrated in a stepwise ethanol gradient, followed
by immersion in methanol containing 0.3% hydrogen peroxide and epitope retrieval with the
Pre-treatment (PT) module (ThermoFisher Scientific) using TEG buffer. The sections were washed in
1% BSA and incubated overnight with the anti-MCM10 primary antibody at 1:250 dilution in 0.1%
BSA. The sections were further washed with PBS and incubated with the HRP-conjugated secondary
antibody (at a 1:500 dilution). Finally, the sections were developed using DAB (ZsBio, Beijing, China)
and counterstained with Meiers Haematoxylin for 2 min followed by de-hydration in an ethanol
gradient and xylene. Mounting was performed with Eukitt mounting medium (Merck) and imaging
was achieved with Carl Zeiss Axio Imager 2 Microscope (Zeiss).
4.15. In Vivo Studies
All animal studies and ethics were followed the guidelines issued and approved by the
University of Macau Animal Ethics Committee (UMARE-012-2016, Permission date: May 2016),
respectively. Eighteen six-week female nude mice received subcutaneous injection with either stable
MCF7-Knockdown cell line or cell line contain vector control. To maintain the tumor, a single dose of
50 µL PBS containing 3 µg estradiol was given on alternative days. The tumors were measured with
calipers. Tumor volume was determined using the formula:
Tumor volume =
pi
6
× L×W2, (1)
where L is the longest diameter and W is the shortest diameter of the excised tumor. At the end of the
experiment, tumors were removed, weighed and photographed.
4.16. Statistical Analysis
The differences observed between the control and treated groups were analyzed using either
One-way ANOVA or unpaired Student t-test (two-tailed) using GraphPad Prism 6 (GraphPad Software,
La Jolla, CA, USA). The results were expressed as the Mean ± SEM (standard error of mean) from
three different replicates and a value of p < 0.05 was considered statistically significant.
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5. Conclusions
Our data demonstrated that MCM10 plays an important in breast cancer progression and is a
potential prognostic biomarker as well as a therapeutic target for breast cancer patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/9/282/s1,
Figure S1: Breast cancer combined datasets with different histological grades, Figure S2: Breast cancer patient
different subtypes, Figure S3: Relative expression of MCM10 in stable Overexpression (OE) in MCF 7 cell lines.
Table S1: Clinicopathological parameters of patient samples used for qPCR analysis of MCM10.
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DNA Deoxyribonucleic acid
MCM Minichromosome maintenance proteins
GEO Gene Expression Omnibus
CDC6 Cell division cycle 6
CDT1 Chromatin licensing and DNA replication factor 1
PCNA Proliferating cell nuclear antigen
HER2 Human Epidermal Growth Factor Receptor 2
GADPH Glyceraldehyde 3-phosphate dehydrogenase
HRP Horseradish peroxidase
CI Confidence interval
PT Pre-treatment
TGE Tris-glycine electrophoresis
DAB 3,3′-diaminobenzidine
ER Estrogen receptor
qPCR Quantitative real time polymerase chain reaction
pCR Pathological complete response
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